tbuckley/cabot-search huggingface dataset:
Characteristics and outcomes of elderly patients with primary CNS lymphoma (PCNSL)
Authors: D. E. Ney, A. S. Reiner, H. D. Skinner, K. S. Panageas, L. M. DeAngelis, L. E. Abrey
Journal: Journal of Clinical Oncology (2009)

2070 Background: The incidence of PCNSL is increasing and is highest in those ≥ 65 years of age. Systemic chemotherapy (CT) ± radiotherapy (RT) improves survival, but treatment related toxicity is greatest in this population. The optimal treatment has yet to be determined. The aim of this study was to characterize older patients with PCNSL at our institution and identify outcomes related to treatment. Methods: We identified patients ≥ 65 years of age treated for PCNSL from 1986 to 2008. Charts were reviewed for demographics, treatment details, tumor progression, and survival. Approval for this study was obtained from the IRB at MSKCC. Results: 174 patients were identified with a median age of 72 years (range: 65–89). 60% of patients had a stereotactic biopsy for diagnosis; 93% had a histologic or cytologic diagnosis. 14 patients had evidence of systemic involvement with detailed staging evaluation. 82% of patients received a high-dose methotrexate (3.5g/m2) regimen, only 13% did not receive CT. Among the patients who received CT, 76% had a radiographic response (CR+PR), 3% had stable disease while 12% progressed. Only 26% had RT as part of initial therapy. CR rate to initial therapy was 67%, 52% of these patients eventually relapsed. Median time to progression was 24 months (range: 1–91). Among the patients who relapsed, 85% received salvage therapy consisting of CT (n = 42), RT (n = 14), or both (n = 7) while 15% received no further treatment. 48% of patients had a CR or PR to salvage therapy while 26% had PD; the remainder were not evaluated. Median overall survival for the entire cohort was 25 months (range: 0.5 to 177+) with a 3-year survival of 36%. 17% developed late treatment-related neurologic toxicity. Administration of RT was associated with the development of neurotoxicity (p &lt; 0.0001). 39 patients remain alive with a median follow-up of 34 months (range: 0.5–177). Conclusions: Elderly patients can receive an aggressive chemotherapeutic regimen with good outcomes. Systemic staging is also valuable as a small subset of patients will have systemic involvement at diagnosis. Clinical trials to optimize treatments for this population are critical. No significant financial relationships to disclose.
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma
Authors: Elena Elimova, Yelena Y. Janjigian, Mary Mulcahy, Daniel V. Catenacci, Mariela A. Blum, Khaldoun Almhanna, J. Randolph Hecht, Jaffer A. Ajani
Journal: Journal of Clinical Oncology (2017)
TCT-25 Efficacy and Safety of Left Atrial Appendage Closure Versus Medical Treatment in Atrial Fibrillation: A Network Metaanalysis From Randomized Trials
Authors: Luis Nombela Franco, Shweta Sahay, Josep Rodés-Cabau, Pilar Jimenez, Pablo Salinas, Corina Biagioni, Ivan Nuñez-Gil, Nieves Gonzalo, Antonio Fernandez-Ortiz, Javier Escaned, Carlos Macaya
Journal: Journal of the American College of Cardiology (2016)
TCT-79 Course of early subclinical leaflet thrombosis after transcatheter aortic valve replacement with or without oral anticoagulation
Authors: Philipp Ruile, Nikolaus Jander, Philipp Blanke, Simon Schoechlin, Jochen Reinöhl, Michael Gick, Mathias Langer, Jonathon Leipsic, Heinz Joachim Buettner, Franz-Josef Neumann, Gregor Pache, Juergen Rothe
Journal: Journal of the American College of Cardiology (2016)
Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma
Authors: Tomer M Mark, Jennifer O'Loughlin, Morton Coleman, David Jayabalan, Roger N Pearse, Faiza Zafar, Scott A Ely, Megan Manco, Patrice Mignott, John P. Leonard, Selina Chen-Kiang, Ruben Niesvizky
Journal: Blood (2010)
TCT-334 Predictors of Outcomes Among Nonagenarians Undergoing Percutaneous Coronary Intervention: A National Veterans Affairs Database Study
Authors: Abhishek Sawant, Vasvi Singh, Kevin Josey, Meg Plomondon, Thomas Maddox, Ali Sheikh, Zaid Said, Bharath Rajagopalan, Deepak Bhatt, John Corbelli
Journal: Journal of the American College of Cardiology (2016)
TCT-459 Real-world experience of biolimus A9- and everolimus-eluting stents in all-comer Korean registries: Patient-oriented and stent-related 3-year outcomes from the multicenter prospective Biolimus-Korea-3000 registry and Excellent-Prime registry
Authors: Ch Kim, Ji-Hyun Jung, Jung-Kyu Han, Han-Mo Yang, Kyung Woo (KW) Park, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Hyo-Soo Kim
Journal: Journal of the American College of Cardiology (2016)
Impact of high-mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo
Authors: J.Y. Kim, E.J. Lee, J. Seo, S.H. Oh
Journal: British Journal of Dermatology (2017)

Vitiligo is attributable to loss of functional melanocytes and is the most common acquired depigmenting disorder. Oxidative stress and intense ultraviolet irradiation are known to aggravate this condition. The nonhistone high‐mobility group box 1 (HMGB1) DNA‐binding protein is a physiological activator of immune responses, cellular proliferation and cell death. Although it is implicated in the pathogenesis of autoimmune diseases and cutaneous disorders, the precise role of HMGB1 in melanocytes has yet to be studied. To elucidate the effect of HMGB1 on melanocytic survival and its involvement in the pathogenesis of vitiligo. Melanocytes were treated with recombinant HMGB1 (rHMGB1). Thereafter, apoptosis‐, autophagy‐ and melanogenesis‐related molecules were detected. Ex vivo skin organ culture was performed after rHMGB1 treatment. Also, levels of HMGB1 were examined in blood and skin specimens from patients with vitiligo. In this study, rHMGB1 increased expression of cleaved caspase 3 and decreased melanin production and expression of melanogenesis‐related molecules. rHMGB1‐induced caspase 3 activation was confirmed through preincubation with a pan‐caspase inhibitor. In ex vivo experiments for the confirmation of HMGB1‐induced melanocyte apoptosis, melanocyte disappearance and increased caspase 3 activation were observed in rHMGB1‐treated skin tissues. In Western blot analysis and enzyme‐linked immunosorbent assay, patients with active vitiligo showed significantly higher blood levels of HMGB1 (vs. healthy controls). Also, greater expression of HMGB1 was observed in vitiliginous skin (vs. uninvolved skin). External stimuli (e.g. oxidative stress and ultraviolet irradiation) may trigger HMGB1 release by keratinocytes, thereby perpetuating vitiligo through HMGB1‐induced melanocytic apoptosis.
Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib.
Authors: T. Moran, J. J. Sanchez, M. A. Molina, J. Bertran-Alamillo, A. Gimenez Capitan, S. Benlloch, M. Taron, B. Massuti, C. Camps, R. Porta, D. Isla, G. Lopez-Vivanco, I. Bover, M. R. Garcia-Campelo, C. D. Rolfo, F. Salazar, E. Carcereny, F. Cardenal, I. Magri, R. Rosell
Journal: Journal of Clinical Oncology (2011)

7590 Background: Progression-free survival (PFS) in EGFR-mutant NSCLC p treated with erlotinib is unpredictable at the individual level. The initial presence of double mutations (EGFR L858R or del 19 plus T790M) is associated with shorter PFS. We hypothesized that the site of mets and/or prior chemotherapy could also influence outcome in these p with double EGFR mutations. Methods: The T790M mutation was assessed in 129 advanced NSCLC p by TaqMan assay in the presence of a peptide-nucleic acid designed to inhibit the amplification of the wild-type allele. Results: De novo T790M mutations were identified in 35% (45 of 129) of EGFR-mutant p before receiving erlotinib. PFS was 12 months (m) for p with double mutations and 18 for p with only L858R or del 19 (P=0.02). The T790M mutation was detected more frequently in p with bone mets (35.6% vs 16.7%; P=0.03). No effect on PFS or MS was observed in p with the T790M mutation according to bone, lung, liver or pleura mets. However, when p with T790M were divided according to the presence of brain mets, PFS was 1 m for 4 p with brain mets vs 13 m for 41 p without brain mets (P=0.002), and MS was 6 m for p with brain mets vs 36 m for those without (P=0.009). Overall, in the multivariate analysis, the presence of the double mutation did not affect the risk of shorter MS (HR, 1.3; P=0.49), but p who had received prior chemotherapy had significantly longer MS (HR, 0.48; P=0.02). Conclusions: The initial double EGFR mutation (EGFR L858R or del 19 plus T790M) is a marker for poor prognosis in p with brain mets. In addition, initial chemotherapy can play a role in the management of NSCLC p with the double EGFR mutation.
Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity
Authors: Enli Liu, Yijiu Tong, Gianpietro Dotti, Barbara Savoldo, Muharrem Muftuoglu, Kayo Kondo, Malini Mukherjee, Jordan S. Orange, Catherine Sobieski, Abdullah Alsuliman, Hila Shaim, Nobuhiko Imahashi, Michael J. Keating, Chitra M. Hosing, Nina Shah, William Wierda, Richard Champlin, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Blood (2015)
TCT-59 Overlapping Bioresorbable Coronary Devices: Immediate Results and 6-month Follow-up of the REPARA Registry
Authors: Felipe Hernandez, Luis Gaviria, joan bassaganyas, Juan Alonso Briales, Juan Francisco Oteo Dominguez, Pedro Martinez-Romero, Leire Andraka, Antonio Serra, MARCOSTOMAS RODRIGUEZ, Alberto Berenguer, Henrique Carvalho, Ricardo Santos, Joao Costa, Francisco Jimenez Cabrera, Armando Bethencourt, Bruno Garcia, Juan Francisco Muñoz, Francisco Bosa, Jaime Elizaga, Koldobika Garcia San Roman, Rosana Hernandez, Jose R. Ruiz Arroyo, Javier Martin-Moreiras, LuisManuel HernandoRomero, Pablo Aguar Carrascosa, Rodrigo Teijeiro, Esther Sánchez Insa
Journal: Journal of the American College of Cardiology (2016)
Risks from less invasive hysterectomy are quantified in study
Authors: Susan Mayor
Journal: BMJ (2016)

Less invasive procedures for hysterectomy are associated with a higher risk of complications than many women may think, a large study of outcomes has found.1

Hysterectomy is one of the most common gynaecological operations, and one in five women in the United Kingdom undergoes the procedure by age 60. All forms of hysterectomy are generally safe, with very few deaths after surgery. Until now, however, no comparison had been made between complications resulting from the three main types of procedure: abdominal, vaginal, …
Clinical Impact of Amyloid Positron Emission Tomography—Is It Worth the Cost?
Authors: Richard J. Caselli, Bryan K. Woodruff
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension?
Authors: James R. Klinger
Journal: European Respiratory Journal (2016)

The role of endothelial-derived nitric oxide (NO) and its downstream signalling pathways in modulating vascular tone and remodelling has been one of the most intriguing areas of vascular biology over the last quarter of a century. Its identification as the endothelial-derived relaxing factor responsible for relaxation of vascular smooth muscle led to the designation of NO as the "molecule of the year" by the journal Science in 1992 [1], and to a Nobel Prize in Physiology or Medicine for L.J. Ignarro, R.F. Furchgott and F. Murad in 1998. It is now well appreciated that the vascular endothelium, in response to a variety of stimuli, synthesises NO from l-arginine by activation of endothelial-derived NO synthase (eNOS), which then diffuses to adjacent vascular smooth muscle cells and activates soluble guanylate cyclase (sGC) leading to synthesis of cyclic guanosine monophosphate (cGMP). The increase in cytoplasmic levels of this secondary messenger activates a variety of mechanisms that decrease intercellular calcium and dephosphorylate the myosin light chain. The overall result is a potent mechanism by which the endothelium can induce vascular smooth muscle relaxation [2]. Plasma nitrate/nitrite levels are lower in patients with pulmonary hypertension and correlate with disease severity <http://ow.ly/JzYD304gWv4>
TCT-216 Bivalrudin vs. Argatroban for treatment of Heparin-induced Thrombocytopenia: A Meta-analysis
Authors: Poonam Velagapudi, Mohit Turagam, Mayank Mittal, Natraj Katta, Harsh Agrawal, Kul Aggarwal, J. Dawn Abbott
Journal: Journal of the American College of Cardiology (2016)
TCT-465 Everolimus eluting stents increase endothelial permeability and prevent maturation – Uncovering the mechanism of Neoatherosclerosis
Authors: Emanuel Harari, Frank Kolodgie, Eduardo Acampado, Liang Guo, Hiroyoshi Mori, Matthew Kutyna, Aloke Finn, Renu Virmani
Journal: Journal of the American College of Cardiology (2016)
Preclinical Analyses Support Clinical Investigation of Combined PD-L1 Blockade and Anti-CD19 CAR T Cell Therapy for the Treatment of NHL
Authors: Ryan P Larson, Michael Ports, Heidi Jessup, Guadalupe Manriquez, Carl Hay, Ross Stewart, Marlon Rebelatto, Robert Hollingsworth, Valerie Odegard
Journal: Blood (2015)
Abstract 16386: Predicting Cardiac Arrest Myocardial Infarction (PreCAMI) in Out of Hospital Cardiac Arrest (OHCA) Survivors Lacking ST Elevations (STE)
Authors: James Fitzgibbon, Francis Pike, Florence Dumas, Michael Scutella, Lindsey Kowalski, Dan Winger, Li Wang, Jon Rittenberger, Jean P Mira, Jonathan Elmer, Catalin Toma, Clifton Callaway, Alain Cariou, Cameron Dezfulian
Journal: Circulation (2015)

Introduction: Coronary angiography (CA) and percutaneous intervention (PCI) after OHCA is recommended for suspected coronary occlusion based on ST elevation (STE) by ECG, yet 20-40% of OHCA patients without STE also have occlusions. Hypothesis: Clinical criteria available prior to CA can be used to create a score to predict whether PCI will be attempted in non-STE OHCA patients with sensitivity (Sn) and specificity (Sp) nearing STE. Attempted PCI in non-STE OHCA will be associated with improved survival and functional outcomes. Methods: We abstracted historical, demographic, resuscitation, ECG and lab data available within 6h of hospitalization in 156 non-STE OHCA who underwent early CA (&lt;24h after OHCA). Logistic regression models tested associations between clinical variables and attempted PCI (model entry criteria p&lt;0.1; stay criteria p&lt;0.15). In these subjects and 304 non-STE OHCA who had delayed/absent CA, propensity adjusted regression examined associations of early CA (regardless of PCI attempt) or PCI attempt with survival or functional recovery (cerebral performance category 1-2, modified Rankin score 0-3 or discharge home or rehabilitation). Independent validation of score Sn and Sp was performed in a cohort where CA in non-STE OHCA is frequent (Cochin registry). Results: 61/156 (39.1%) OHCA subjects without STE had attempted PCI. We derived a 4 variable (initial troponin, male sex, VF/VT presentation, epinephrine doses during CPR) parsimonious model (AUROC 0.78) which predicted PCI attempt with Sn 83%/Sp 51% comparing favorably to STE at our center (Sn 62%/Sp 77%). In Cochin 111/467 (24%) of CA resulted in PCI. Score validation in 407 OHCA with complete data yielded Sn 68%/Sp 50% for predicting PCI use in CA. Attempted PCI, but not CA alone, was associated with improved outcomes (US cohort). ( Table ). Conclusion: We've validated a 4 variable score which predicts PCI use in OHCA without STE. PCI use in this population is associated with improved outcomes.
BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD)
Authors: Amin Alousi, Daniel J. Weisdorf, Brent R. Logan, Javier Bolanos-Meade, Steven C. Goldstein, Vincent T Ho, Brandon Hayes-Lattin, John R. Wingard, Mary M. Horowitz, John E. Levine
Journal: Blood (2008)
Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis
Authors: Jonathan A. Kropski, Lisa R. Young, Joy D. Cogan, Daphne B. Mitchell, Lisa H. Lancaster, John A. Worrell, Cheryl Markin, Na Liu, Wendi R. Mason, Tasha E. Fingerlin, David A. Schwartz, William E. Lawson, Timothy S. Blackwell, John A. Phillips, James E. Loyd
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
TCT-457 Paclitaxel - eluting stents vs Everolimus - eluting Coronary Stents in a Diabetic population: 2 Years Follow-up of TUXEDO-India Trial
Authors: Upendra Kaul, Dr. Rajpal K. Abhaichand, Tejas Patel, Darshan Banker, Atul Abhyankar, Ajit Mullasari, Sanjay Shah, Rajneesh Jain, None premchand rajendra kumar, C.G. Bahuleyan, Priyadarshini Arambam, Sripal Bangalore
Journal: Journal of the American College of Cardiology (2016)
NARROW BAND IMAGING PARA LA PREDICCIÓN IN VIVO DE LA HISTOLOGÍA DE LOS PÓLIPOS DE COLON: PRUEBA PILOTO DE UNA NUEVA HERRAMIENTA ON-LINE PARA EL APRENDIZAJE DE LA CLASIFICACIÓN NICE
Authors: F Díaz Jaime, MT Blazquez Martinez, B Navarro Navarro, N Alonso Lazaro, M Ponce Romero, L Argüello Viudez, V Pons Beltrán, M Bustamante Balén
Journal: Endoscopy (2016)

Introducción: los resultados del diagnóstico óptico (DO) de las lesiones diminutas del colon usando NBI (clasificación NICE) obtenidos fuera de centros de excelencia no son buenos. Una explicación es el fracaso en los métodos de enseñanza de la técnica.
Postoperative morbidity after completion surgery in patients undergoing chemoradiotherapy for locally advanced cervical carcinoma
Authors: C. Touboul, C. Uzan, S. Gouy, A. Rey, A. Maugen, Y. Delpech, O. Chanelles, P. Pautier, C. Lhomme, P. Duvillard, C. Haie-Meder, P. Morice
Journal: Journal of Clinical Oncology (2009)

5595 Background: The aim of this study was to evaluate the morbidity rate in patients undergoing completion surgery after homogeneous chemoradiation therapy (CRT) for locally advanced stage cervical cancer. Methods: Patients fulfilling following inclusion criteria were studied: 1. Stage IB2-IVA cervical carcinoma; 2. Tumor confined radiologically initially to the pelvic cavity; 3. Pelvic external radiation therapy with delivery of 45 Gy in pelvic cavity with concomitant chemotherapy (cisplatin 40 mg/m 2 /week) followed by utero-vaginal brachytherapy; 4. Completion surgery after the end of radiation therapy including at least a hysterectomy. Modalities of this completion surgery depended on the presence, location and size of residual disease. Results: One-hundred and fifty patients treated between 1998 and 2007 fulfilled inclusion criteria. Modalities of hysterectomy performed were: extrafascial hysterectomy in 106 (71%) patients and radical hysterectomy in 44 (29%). Para-aortic lymphadenectomy was performed in 131 (87%) patients and pelvic lymphadenectomy in 34 (23%) patients. Thirty-four (23%) patients had macroscopic (&gt; 1 cm) residual disease on pathologic examination. Twenty-five (23%) patients had post-operative complications (in whom 17 severe morbidity requiring surgical or radiological treatment). Presence of residual disease was the only factor associated with overall morbidity rate in univariate and multivariate analysis. The use of radical hysterectomy and pelvic lymphadenectomy increased significantly the rate of severe morbidity (particularly bowel and urinary tract morbidity). Conclusions: In the present study involving a large number of patients undergoing completion surgery after homogeneous CRT in locally advanced cervical carcinoma the morbidity rate is important. Radical hysterectomy and pelvic lymphadenectomy increase the rate of severe morbidity. The interest on the survival of this completion surgery should be evaluated in prospective trial. No significant financial relationships to disclose.
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
Authors: Jennifer L. Bishop, Daksh Thaper, Sepideh Vahid, Alastair Davies, Kirsi Ketola, Hidetoshi Kuruma, Randy Jama, Ka Mun Nip, Arkhjamil Angeles, Fraser Johnson, Alexander W. Wyatt, Ladan Fazli, Martin E. Gleave, Dong Lin, Mark A. Rubin, Colin C. Collins, Yuzhuo Wang, Himisha Beltran, Amina Zoubeidi
Journal: Cancer Discovery (2016)

Abstract Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain elusive. Using a unique model of AR pathway inhibitor–resistant prostate cancer, we identified AR-dependent control of the neural transcription factor BRN2 (encoded by POU3F2) as a major driver of NEPC and aggressive tumor growth, both in vitro and in vivo. Mechanistic studies showed that AR directly suppresses BRN2 transcription, which is required for NEPC, and BRN2-dependent regulation of the NEPC marker SOX2. Underscoring its inverse correlation with classic AR activity in clinical samples, BRN2 expression was highest in NEPC tumors and was significantly increased in castration-resistant prostate cancer compared with adenocarcinoma, especially in patients with low serum PSA. These data reveal a novel mechanism of AR-dependent control of NEPC and suggest that targeting BRN2 is a strategy to treat or prevent neuroendocrine differentiation in prostate tumors. Significance: Understanding the contribution of the AR to the emergence of highly lethal, drug-resistant NEPC is critical for better implementation of current standard-of-care therapies and novel drug design. Our first-in-field data underscore the consequences of potent AR inhibition in prostate tumors, revealing a novel mechanism of AR-dependent control of neuroendocrine differentiation, and uncover BRN2 as a potential therapeutic target to prevent emergence of NEPC. Cancer Discov; 7(1); 54–71. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1
A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).
Authors: Robert Chen, Joycelynne Palmer, Leslie Popplewell, Ni-Chun Tsai, Amrita Krishnan, Margaret O'Donnell, Ryotaro Nakamura, Eileen Smith, Stephen J Forman, Auayporn P. Nademanee
Journal: Blood (2009)
TCT-63 Impact of Chronic Total Occlusions on Revascularization Scores and Outcome Prediction
Authors: Bjorn Redfors, Tullio Palmerini, Adriano Caixeta, Girma Ayele, Dominic Francese, Roxana Mehran, Emmanouil Brilakis, Ajay Kirtane, Dimitri Karmpaliotis, Gregg Stone, Philippe Généreux
Journal: Journal of the American College of Cardiology (2016)